Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 1, 2014, Pages 80-86

  Falantes, Jose F ^a   Calderón, Cristina ^a   Márquez Malaver, Francisco J ^a   Aguilar Guisado, Manuela ^a   Martín Peña, Almudena ^a   Martino, María L ^a   Montero, Isabel ^a   González, Jose ^a   Parody, Rocío ^a   Pérez Simón, Jose A ^a   Espigado, Ildefonso ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Acute Myeloid Leukemia; Aspergillosis; Azacitidine; Myelodysplastic Syndrome; Prophylaxis

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; BLAST CELL; CANCER CHEMOTHERAPY; COHORT ANALYSIS; DISEASE DURATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; KARYOTYPE; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PROBABILITY; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; VERY ELDERLY;

ACUTE MYELOID LEUKEMIA; ASPERGILLOSIS; AZACITIDINE; MYELODYSPLASTIC SYNDROME; PROPHYLAXIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84892825200     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.09.014     Document Type: Article

References (27)

1. D. Neofytos, K. Lu, and A. Hatfield-Seung et al. Epidemiology, outcomes, and risk of invasive fungal infections in adult patients with acute myelogenous leukemia after induction therapy Diagn Microbiol Infect Dis 75 2013 144 149
2. O.A. Cornely, J. Maertens, and D.J. Winston et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 2007 348 359
3. O.A. Cornely, A. Böhme, and D. Buchheidt et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology Haematologica 94 2009 113 122
4. J.J. Vehreschild, M.J. Rüping, and H. Wisplinghoff et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort J Antimicrob Chemother 65 2010 1466 1471
5. A.G. Freifeld, and E.J. Bow et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America Clin Infect Dis 52 2011 e56 e93
6. J. Maertens, O. Marchetti, and R. Herbrecht et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update Bone Marrow Transplant 46 2001 709 718
7. National Comprehensive Cancer Network. NCCN Guidelines for Supportive Care: Prevention and Treatment of Cancer-Related Infections, version 1.2013. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
8. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study Lancet Oncol 10 2009 223 232
9. A. Quintás-Cardama, F. Ravandi, and T. Liu-Dumlao et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia Blood 120 2012 4840 4845
10. L.H. Van der Helm, E.R. Scheepers, and N.J. Veeger et al. Azacitidine might beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients J Hematol Oncol 6 2013 29
11. T. Field, J. Perkins, and Y. Huang et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation Bone Marrow Transplant 45 2010 255 260
12. P. Fenaux, D. Bowen, and N. Gatterman et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion Leuk Res 34 2010 1410 1416
13. J.H. Lee, K.H. Lee, and J.H. Lee et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome Leuk Res 35 2011 499 503
14. D. Merkel, K. Filanovsky, and A. Gafter-Gvili et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study Am J Hematol 88 2013 130 134
15. S.H. Swerdlow, E. Campo, and N.L. Harris et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue 4th ed 2008 IARC Lyon, France
16. B. De Pauw, T.J. Walsh, and J.P. Donnelly et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 2008 1813 1821
17. J.M. Cisneros, I. Espigado, and A. Rivero et al. Empirical antifungal therapy in selected patients with persistent fever and neutropenia Enferm Infecc Microbiol Clin 23 2005 609 614
18. M. Aguilar-Guisado, A. Martín-Peña, and I. Espigado et al. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach Haematologica 97 2012 464 471
19. B.D. Cheson, P.L. Greenberg, and J.M. Bennett et al. Clinical application and proposal for the modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 2006 419 425
20. H. Döhner, E.H. Estey, and S. Amadori et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel on behalf of the European LeukemiaNet Blood 115 2010 453 474
21. Dean AG, Sullivan KM, Soe MM. OpenEpi: open source of epidemiologic statistics for public health, version 2.3.21. Available at: www.OpenEpi.com. Accessed: October 17, 2012.
22. R. Wang, S.W. Lagakos, and R.J. Gray Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring Biostatistics 11 2010 676 692
23. G. Chatellier, E. Zapletal, and D. Lemaitre et al. The number needed to treat: a clinically useful nomogram in its proper context BMJ 312 1996 426 429
24. L. Pagano, M. Caira, and A. Candoni et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study Haematologica 95 2010 644 650
25. L.R. Silverman, D.R. McKenzie, and B.L. Peterson et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, 9221 by the Cancer and Leukemia Group B J Clin Oncol 24 2006 3895 3903
26. D.P. Steensma, and R.M. Stone Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes Hematol Oncol Clin North Am 24 2010 389 406
27. L.R. Silverman, P. Fenaux, and G.J. Mufti et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes Cancer 117 2011 2697 2702